Imigran

Sumatriptan, the active ingredient in Imigran, is a Triptan presented as a subcutaneous injection for acute treatment of migraine attacks in adults. It works by targeting specific serotonin receptors to relieve headache pain and associated symptoms quickly and improve quality of life.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution. Imigran is manufactured under GMP conditions and is available for export to multiple regions.

Sumatriptan is a selective 5‑HT1B/1D receptor agonist used in the acute management of migraine. Migraine with aura: provides rapid relief of headache pain and associated neurological symptoms. Migraine without aura: reduces headache intensity and duration, improving functional ability. Migraine-associated nausea: helps alleviate accompanying nausea and vomiting. Migraine with photophobia: decreases light sensitivity, contributing to overall symptom relief. Migraine with phonophobia: lessens sound sensitivity, aiding patient comfort during attacks.

Sumatriptan may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Injection site pain: mild discomfort at the injection site. - Tingling or paresthesia: transient sensation of pins and needles. - Flushing: temporary warmth and redness of the skin. - Nausea: mild upset stomach. Serious or Rare Side Effects: - Chest pain or coronary vasospasm: may indicate cardiac ischemia. - Serotonin syndrome: rare but potentially life‑threatening reaction when combined with other serotonergic agents.

Before using Imigran, consider the following precautions. - Cardiovascular assessment: evaluate for ischemic heart disease before use. - Concomitant serotonergic drugs: avoid or monitor for serotonin syndrome. - Pregnancy: use only if potential benefit justifies risk. - Renal impairment: consider dose adjustment in severe renal dysfunction. - Drug interactions: review all concurrent medications for contraindications. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sumatriptan can interact with several medications; review patient medication lists carefully. Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Ergot alkaloids: additive vasoconstriction may cause coronary spasm. - Other triptans: combined use increases risk of serious cardiovascular events. Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance hypotensive effect. - Calcium channel blockers (dihydropyridines): may increase vasoconstrictive response.